Institut National De La Sante Et De La Recherche Medicale

Universidad De Granada

Fondation Imagine

Assistance Publique-Hopitaux De Paris

Assistance Publique - Hopitaux De Paris (Aphp)

Université De Paris

Universite Paris Cité

Inserm

Antonio Segura Carretero

Laurence Legeai-Mallet

Maria De La Luz Cadiz Gurrea

FGFR3-related chondrodysplasias represent a group of rare diseases. Among them, achondroplasia, a nonlethal form of chondrodysplasia, is the most common type of dwarfism. The mutation, which produce an increase of FGFR3 function, affects many tissues, most strikingly the cartilaginous growth plate and bone in the growing skeleton, leading to a variety of manifestations and complications. In attempt to find a new therapeutic approach for FGFR3-related chondrodysplasia, the inventors purified (−)-epicatechin fromand showed that (−)-epicatechin treatment significantly increases the length of the Fgfr3femurs comparing to Fgfr3femurs and improves the whole growth plate cartilage. The present invention thus relates to the use of (−)-epicatechin for the treatment of FGFR3-related chondrodysplasias.

Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias

Growing community of inventors

Granada, Spain

Antonio Segura Carretero